Bruce Jackson

Benchmark

Bruce Jackson is an analyst from Benchmark Ranked #1691 out of 4639 analysts, they have issued 5 stock ratings with a success rate of 94.30% and an average return of 1.29%.

With 5 ratings to date, Bruce Jackson is beginning to establish credibility in the market sector. They have achieved a success rate of 94.30% and an average return of 1.29%, highlighting promising potential as their track record develops further.

#1691

Out of 4639

5

Total Ratings

+94.30%

Success Rate

+1.29%

Average Return

Recent Ratings Analysis

NEO

Apr 29, 2026

Target

$11.00

Current

$9.26

Performance

3.35%

Bruce Jackson rated NEO as Buy on Apr 29, 2026, setting a price target of 11. Shares have remained stable near 9.26, leaving the 11 target still in play.

CV

Mar 27, 2026

Target

$10.00

Current

$7.08

Performance

-5.73%

On Mar 27, 2026, CV was given a Speculative Buy rating by Bruce Jackson, with a target price of 10. Despite the Buy call, shares fell from 7.08 to 7.08, challenging the optimistic stance.

ABT

Oct 10, 2025

Target

$145.00

Current

$90.63

Performance

-31.64%

ABT received a Buy rating from Bruce Jackson on Oct 10, 2025, aiming for 145. The rating hasn’t played out as hoped, with the stock trading 31.64% below expectations.

BLTE

Mar 26, 2025

Target

$80.00

Current

$159.16

Performance

144.07%

On Mar 26, 2025, Bruce Jackson published a Buy outlook on BLTE, with a target of 80. Shares gained 144.07%, underscoring the accuracy of the bullish outlook toward 80.

HBIO

Mar 24, 2025

Target

$4.50

Current

$6.38

Performance

6.53%

Bruce Jackson on Mar 24, 2025 assigned HBIO a Speculative Buy rating, with a price target of 4.5. The Buy call aligned well with market performance, producing a gain of 6.53%.

HUMA

Feb 27, 2025

Target

—

Current

$0.84

Performance

-75.02%

On Feb 27, 2025, Bruce Jackson reaffirmed HUMA with a Buy rating, targeting null. Shares slid 75.02% despite the recommendation, highlighting downside risks.

EXAS

Jan 13, 2025

Target

$65.00

Current

$104.91

Performance

79.30%

EXAS was rated Buy by Bruce Jackson on Jan 13, 2025, with a price objective of 65. A bullish response from the market helped close the gap of -39.91 to the target.

UNCY

Nov 22, 2024

Target

$3.00

Current

$7.66

Performance

44.53%

On Nov 22, 2024, Bruce Jackson initiated coverage on UNCY with a Speculative Buy rating and target of 3. The stock’s climb of 44.53% since the call highlights the foresight in the rating.

CLNN

Nov 22, 2024

Target

$84.00

Current

$6.16

Performance

47.72%

Bruce Jackson issued a Buy recommendation for CLNN on Nov 22, 2024, price target set at 84. Investors following the Buy call captured upside momentum, with shares now at 6.16.

VNRX

Nov 22, 2024

Target

—

Current

$2.62

Performance

-83.50%

On Nov 22, 2024, VNRX was evaluated by Bruce Jackson, who gave a Hold rating and target of null. The Hold call avoided chasing into subsequent weakness of 83.50%.

MLSS

Nov 20, 2024

Target

$1.25

Current

$0.31

Performance

-54.28%

Bruce Jackson rated MLSS as Speculative Buy on Nov 20, 2024, setting a price target of 1.25. The stock has underperformed, dropping 54.28% despite the bullish target of 1.25.

BFRI

Nov 15, 2024

Target

$7.00

Current

$1.08

Performance

47.14%

On Nov 15, 2024, BFRI was given a Buy rating by Bruce Jackson, with a target price of 7. The stock rallied 47.14% after the rating, narrowing the gap to the target of 7 and validating the bullish stance.

HOTH

Oct 11, 2024

Target

$3.00

Current

$0.75

Performance

-0.65%

HOTH received a Speculative Buy rating from Bruce Jackson on Oct 11, 2024, aiming for 3. Price action was muted, as shares hovered around 0.7461 despite the bullish outlook.

GDTC

Oct 10, 2024

Target

$5.00

Current

$1.00

Performance

-50.40%

On Oct 10, 2024, Bruce Jackson published a Speculative Buy outlook on GDTC, with a target of 5. Market action contradicted the Buy thesis, as shares slipped to 0.997.

BIOL

Oct 02, 2024

Target

$0.40

Current

$0.02

Performance

15.27%

Bruce Jackson on Oct 02, 2024 assigned BIOL a Speculative Buy rating, with a price target of 0.4. The Buy call aligned well with market performance, producing a gain of 15.27%.

CDIO

Aug 27, 2024

Target

$2.00

Current

$1.79

Performance

-84.88%

On Aug 27, 2024, Bruce Jackson reaffirmed CDIO with a Speculative Buy rating, targeting 2. Shares slid 84.88% despite the recommendation, highlighting downside risks.

RVPH

Aug 26, 2024

Target

$17.00

Current

$0.87

Performance

-95.62%

RVPH was rated Speculative Buy by Bruce Jackson on Aug 26, 2024, with a price objective of 17. This case shows how bullish projections can fail, with the stock now below 0.8705.

TNON

Aug 14, 2024

Target

$3.00

Current

$0.76

Performance

-79.46%

On Aug 14, 2024, Bruce Jackson initiated coverage on TNON with a Speculative Buy rating and target of 3. The Buy call has yet to be validated as shares remain 2.24 away from the target.

MOVE

Jul 30, 2024

Target

$2.00

Current

$15.90

Performance

-75.23%

Bruce Jackson issued a Speculative Buy recommendation for MOVE on Jul 30, 2024, price target set at 2. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Frequency Asked Questions

Who is Bruce Jackson?

Bruce Jackson is an analyst from Benchmark.

What is Bruce Jackson's success rate?

Bruce Jackson currently has a success rate of +94.30%.

How many ratings has Bruce Jackson issued?

Bruce Jackson has issued 5 stock ratings so far.

What is the average return of Bruce Jackson's calls?

Their stock ratings have generated an average return of +1.29%.

What is Bruce Jackson's ranking?

Bruce Jackson is ranked #1691 out of 4639 analysts.

What types of ratings does Bruce Jackson give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Bruce Jackson?

You can follow Bruce Jackson by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Bruce Jackson?

Their latest rating was a Buy on NEO issued on 2026-04-29.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep